Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

SeaStar Medical Holding Q3 2026 Results: Net Loss of $4.53M, Loss Widens

SeaStar Medical reported a net loss of $11.8 million for the nine months ended September 30, 2026, compared to $9.2 million in the prior year period, driven by increased research and development expenses. Total revenue grew to $1.7 million from $0.8 million year-over-year, while cash reserves decreased significantly to $4.0 million from $12.0 million at the start of the year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.60.2
Gross profit0.60.2
Profit before tax-4.5-3.5
Net income-4.5-3.5
EPS (diluted, $ a share)$-1.03$-1.30

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+217.5%
Gross margin92.4%
Source

10-Q filed with the SEC, NASDAQ: ICU. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

SeaStar Medical Holding Corp: key numbers

Share price
$0.7810Close, Nov 17
Market cap
$4.15M
Shares outstanding
5.32MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from SeaStar Medical Holding Corp

All →
8:00 AM ET 8-K
Financial Results

SeaStar Medical Holding Financial Results

SeaStar Medical reported Q3 2026 financial results, highlighted by a 247% increase in net revenue to $635,000 driven by adoption of its QUELIMMUNE therapy. The company also announced that its NEUTRALIZE-AKI pivotal clinical trial for adult patients is nearly 75% enrolled and it has submitted the first module of its PMA application to the FDA.

Term
Q3 2026

“The strength of the QUELIMMUNE therapy adoption in this ultra-rare pediatric AKI market provides great promise for our pipeline indications. And we continue to build momentum in educating the critical care pediatric health care community.”

Eric Schlorff, CEO of SeaStar Medical

“The NEUTRALIZE-AKI pivotal clinical trial has enrolled nearly 75% of its intended 339 patients, and we have already submitted the first module of the premarket approval application to the FDA in hopes that our modular submission will speed this potential approval.”

Eric Schlorff, CEO of SeaStar Medical
8:31 AM ET 8-K
Business Update

SeaStar Medical Holding Business Update

SeaStar Medical announced that the FDA's Center for Biologics Evaluation and Research (CBER) determined the QUELIMMUNE Pediatric SAVE Surveillance Registry has fulfilled its post-approval study requirements. This decision allows hospitals to use the QUELIMMUNE therapy for pediatric sepsis-associated acute kidney injury without the research infrastructure previously required by the registry, significantly expanding patient access.

Counterparty
FDA
4:21 PM ET 8-K
Capital Raise

SeaStar Medical Holding Capital Raise of $3.3M

SeaStar Medical entered into agreements with warrant holders to exercise outstanding warrants for 854,002 shares at a reduced price of $3.866 per share, generating $3.3 million in gross proceeds. In exchange for the cash exercise, the company issued new unregistered Series A and Series B warrants for an additional 1,708,004 shares. The proceeds are intended for general corporate purposes, including working capital and capital expenditures.

Value
$3.3M
Counterparty
H.C. Wainwright & Co., LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.